Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms

Molecular Metabolism

Volumn 3, Issue 2, 2014, Pages 94-108

  Stirban, Alin ^a   Gawlowski, Thomas ^b   Roden, Michael ^c,d  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b UNIVERSITY OF PADERBORN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Advanced glycation endproducts; Endothelium; Vascular

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; CONFORMATION; CROSS LINKING; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; INFLAMMATION; INFLAMMATORY CELL; METABOLISM; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PERICYTE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE; VASCULAR SMOOTH MUSCLE;

EID: 84895801260     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.11.006     Document Type: Review

References (195)

1. Seshasai S.R., Kaptoge S., Thompson A., Di A.E., Gao P., Sarwar N., Whincup P.H., Mukamal K.J., Gillum R.F., Holme I., Njolstad I., Fletcher A., Nilsson P., Lewington S., Collins R., Gudnason V., Thompson S.G., Sattar N., Selvin E., Hu F.B., Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. New England Journal of Medicine 2011, 364:829-841.
2. Hobbs F.D. Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals. Atherosclerosis Supplements 2006, 7:29-32.
3. Nin J.W., Jorsal A., Ferreira I., Schalkwijk C.G., Prins M.H., Parving H.H., Tarnow L., Rossing P., Stehouwer C.D. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011, 34:442-447.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
5. Tan K.C., Chow W.S., Ai V.H., Metz C., Bucala R., Lam K.S. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002, 25:1055-1059.
6. Ramasamy R., Yan S.F., Schmidt A.M. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascular Pharmacology 2012, 57:160-167.
7. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997, 46(Suppl. 2):S19-S25.
8. Vlassara H., Palace M.R. Glycoxidation: the menace of diabetes and aging. Mount Sinai Journal of Medicine 2003, 70:232-241.
9. Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Research and Clinical Practice 2005, 67:3-21.
10. Mendez J.D., Xie J., Aguilar-Hernandez M., Mendez-Valenzuela V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Molecular and Cellular Biochemistry 2010, 341:33-41.
11. Miyata T., Kurokawa K., van Ypersele de S.C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. Journal of the American Society of Nephrology 2000, 11:1744-1752.
12. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J., Dahms W., Cleary P.A., Lachin J., Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT skin collagen ancillary study group. Diabetes control and complications trial. Diabetes 1999, 48:870-880.
13. Schiekofer S., Andrassy M., Chen J., Rudofsky G., Schneider J., Wendt T., Stefan N., Humpert P., Fritsche A., Stumvoll M., Schleicher E., Haring H.U., Nawroth P.P., Bierhaus A. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003, 52:621-633.
14. Vlassara H., Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996, 45(Suppl. 3):S65-S66.
15. Giardino I., Edelstein D., Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. Journal of Clinical Investigation 1994, 94:110-117.
16. Hunter S.J., Boyd A.C., O'Harte F.P., McKillop A.M., Wiggam M.I., Mooney M.H., McCluskey J.T., Lindsay J.R., Ennis C.N., Gamble R., Sheridan B., Barnett C.R., McNulty H., Bell P.M., Flatt P.R. Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. Diabetes 2003, 52:492-498.
17. Howard M.J., Smales C.M. NMR analysis of synthetic human serum albumin alpha-helix 28 identifies structural distortion upon amadori modification. Journal of Biological Chemistry 2005, 280:22582-22589.
18. Yeboah F.K., Alli I., Yaylayan V.A., Yasuo K., Chowdhury S.F., Purisima E.O. Effect of limited solid-state glycation on the conformation of lysozyme by ESI-MSMS peptide mapping and molecular modeling. Bioconjugate Chemistry 2004, 15:27-34.
19. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
20. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochemical Journal 1999, 344(Pt. 1):109-116.
21. Hegab Z., Gibbons S., Neyses L., Mamas M.A. Role of advanced glycation end products in cardiovascular disease. World Journal of Cardiology 2012, 4:90-102.
22. Taneda S., Monnier V.M. ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clinical Chemistry 1994, 40:1766-1773.
23. Hartog J.W., Voors A.A., Bakker S.J., Smit A.J., Van Veldhuisen D.J. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. European Journal of Heart Failure 2007, 9:1146-1155.
24. Onorato J.M., Thorpe S.R., Baynes J.W. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Annals of the New York Academy of Sciences 1998, 854:277-290.
25. Uribarri J., Woodruff S., Goodman S., Cai W., Chen X., Pyzik R., Yong A., Striker G.E., Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. Journal of the American Dietetic Association 2010, 110:911-916.
26. Forster A., Kuhne Y., Henle T. Studies on absorption and elimination of dietary maillard reaction products. Annals of the New York Academy of Sciences 2005, 1043:474-481.
27. Foerster A., Henle T. Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyrraline. Biochemical Society Transactions 2003, 31:1383-1385.
28. Erbersdobler H.F., Faist V. Metabolic transit of Amadori products. Nahrung 2001, 45:177-181.
29. Koschinsky T., He C.J., Mitsuhashi T., Bucala R., Liu C., Buenting C., Heitmann K., Vlassara H. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6474-6479.
30. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., Dardaine V., Peppa M., Rayfield E.J. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:15596-15601.
31. Uribarri J., Peppa M., Cai W., Goldberg T., Lu M., He C., Vlassara H. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. Journal of the American Society of Nephrology 2003, 14:728-731.
32. Uribarri J., Peppa M., Cai W., Goldberg T., Lu M., Baliga S., Vassalotti J.A., Vlassara H. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. American Journal of Kidney Diseases 2003, 42:532-538.
33. Cerami C., Founds H., Nicholl I., Mitsuhashi T., Giordano D., Vanpatten S., Lee A., Al-Abed Y., Vlassara H., Bucala R., Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:13915-13920.
34. Turk N., Mornar A., Mrzljak V., Turk Z. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria. Diabetes and Metabolism 2004, 30:187-192.
35. Smedsrod B., Melkko J., Araki N., Sano H., Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochemical Journal 1997, 322(Pt. 2):567-573.
36. Semba R.D., Nicklett E.J., Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype?. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2010, 65:963-975.
37. Ahmed N., Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes, Obesity and Metabolism 2007, 9:233-245.
38. Munch G., Schinzel R., Loske C., Wong A., Durany N., Li J.J., Vlassara H., Smith M.A., Perry G., Riederer P. Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of Neural Transmission 1998, 105:439-461.
39. de G.L., Hinkema H., Westra J., Smit A.J., Kallenberg C.G., Bijl M., Posthumus M.D. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Research and Therapy 2011, 13:R205.
40. Meerwaldt R., Graaff R., Oomen P.H., Links T.P., Jager J.J., Alderson N.L., Thorpe S.R., Baynes J.W., Gans R.O., Smit A.J. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004, 47:1324-1330.
41. Petrovic R., Futas J., Chandoga J., Jakus V. Rapid and simple method for determination of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in urine using gas chromatography/mass spectrometry. Biomedical Chromatography 2005, 19:649-654.
42. Ahmed N., Babaei-Jadidi R., Howell S.K., Beisswenger P.J., Thornalley P.J. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005, 48:1590-1603.
43. Thornalley P.J. Measurement of protein glycation, glycated peptides, and glycation free adducts. Peritoneal Dialysis International 2005, 25:522-533.
44. Kislinger T., Humeny A., Peich C.C., Becker C.M., Pischetsrieder M. Analysis of protein glycation products by MALDI-TOF/MS. Annals of the New York Academy of Sciences 2005, 1043:249-259.
45. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., Sivitz W., Monnier V.M. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111.
46. Smit A.J., Gerrits E.G. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Current Opinion in Nephrology and Hypertension 2010, 19:527-533.
47. Lutgers H.L., Graaff R., Links T.P., Ubink-Veltmaat L.J., Bilo H.J., Gans R.O., Smit A.J. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006, 29:2654-2659.
48. McIntyre N.J., Chesterton L.J., John S.G., Jefferies H.J., Burton J.O., Taal M.W., Fluck R.J., McIntyre C.W. Tissue-advanced glycation end product concentration in dialysis patients. Clinical Journal of the American Society of Nephrology 2010, 5:51-55.
49. Meerwaldt R., Links T.P., Graaff R., Hoogenberg K., Lefrandt J.D., Baynes J.W., Gans R.O., Smit A.J. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005, 48:1637-1644.
50. Cai W., Gao Q.D., Zhu L., Peppa M., He C., Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Molecular Medicine 2002, 8:337-346.
51. Duell P.B., Oram J.F., Bierman E.L. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991, 40:377-384.
52. Wever R.M., Luscher T.F., Cosentino F., Rabelink T.J. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998, 97:108-112.
53. Xu B., Ji Y., Yao K., Cao Y.X., Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clinical Science (London) 2005, 109:439-446.
54. Vlassara H. Advanced glycation end-products and atherosclerosis. Annals of Medicine 1996, 28:419-426.
55. Stirban A. The role of AGEs and ROS in atherosclerosis. Herz 2010, 35:170-180.
56. Stirban A., Rosen P., Tschoepe D. Complications of type 1 diabetes: new molecular findings. Mount Sinai Journal of Medicine 2008, 75:328-351.
57. Charonis A.S., Reger L.A., Dege J.E., Kouzi-Koliakos K., Furcht L.T., Wohlhueter R.M., Tsilibary E.C. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990, 39:807-814.
58. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes/Metabolism Research and Reviews 2001, 17:189-212.
59. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., Nawroth P.P. Understanding RAGE, the receptor for advanced glycation end products. Journal of Molecular Medicine 2005, 83:876-886.
60. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
61. Griscavage J.M., Wilk S., Ignarro L.J. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3308-3312.
62. Mohamed A.K., Bierhaus A., Schiekofer S., Tritschler H., Ziegler R., Nawroth P.P. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999, 10:157-167.
63. Kowluru R.A. Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions. Life Sciences 2005, 76:1051-1060.
64. Aronson D., Rayfield E.J. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovascular Diabetology 2002, 1:1.
65. Bucala R., Mitchell R., Arnold K., Innerarity T., Vlassara H., Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. Journal of Biological Chemistry 1995, 270:10828-10832.
66. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:6434-6438.
67. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:9441-9445.
68. Steinbrecher U.P., Witztum J.L. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984, 33:130-134.
69. Klein R.L., Laimins M., Lopes-Virella M.F. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 1995, 44:1093-1098.
70. Sobenin I.A., Tertov V.V., Koschinsky T., Bunting C.E., Slavina E.S., Dedov I.I., Orekhov A.N. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 1993, 100:41-54.
71. Bowie A., Owens D., Collins P., Johnson A., Tomkin G.H. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?. Atherosclerosis 1993, 102:63-67.
72. Wu M., Chen Y., Wilson K., Chirindel A., Ihnat M.A., Yu Y., Boulton M.E., Szweda L.I., Ma J.X., Lyons T.J. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Investigative Ophthalmology and Visual Science 2008, 49:2679-2685.
73. Du M., Wu M., Fu D., Yang S., Chen J., Wilson K., Lyons T.J. Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy?. Diabetologia 2013, 56:2318-2328.
74. Lyons T.J., Li W., Wells-Knecht M.C., Jokl R. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 1994, 43:1090-1095.
75. Wu M., Yang S., Elliott M.H., Fu D., Wilson K., Zhang J., Du M., Chen J., Lyons T. Oxidative and endoplasmic reticulum stresses mediate apoptosis induced by modified LDL in human retinal Muller cells. Investigative Ophthalmology and Visual Science 2012, 53:4595-4604.
76. Lewis P., Stefanovic N., Pete J., Calkin A.C., Giunti S., Thallas-Bonke V., Jandeleit-Dahm K.A., Allen T.J., Kola I., Cooper M.E., de Haan J.B. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 2007, 115:2178-2187.
77. Salminen A., Kauppinen A., Hyttinen J.M., Toropainen E., Kaarniranta K. Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization. Molecular Medicine 2010, 16:535-542.
78. Oshitari T., Hata N., Yamamoto S. Endoplasmic reticulum stress and diabetic retinopathy. Vascular Health and Risk Management 2008, 4:115-122.
79. Fu D., Wu M., Zhang J., Du M., Yang S., Hammad S.M., Wilson K., Chen J., Lyons T.J. Mechanisms of modified LDL-induced pericyte loss and retinal injury in diabetic retinopathy. Diabetologia 2012, 55:3128-3140.
80. Rabinowitz J.D., White E. Autophagy and metabolism. Science 2010, 330:1344-1348.
81. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New England Journal of Medicine 1988, 318:1315-1321.
82. Lu C., He J.C., Cai W., Liu H., Zhu L., Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:11767-11772.
83. Pugliese G., Pricci F., Iacobini C., Leto G., Amadio L., Barsotti P., Frigeri L., Hsu D.K., Vlassara H., Liu F.T., Di M.U. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB Journal 2001, 15:2471-2479.
84. Li J.J., Dickson D., Hof P.R., Vlassara H. Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis. Molecular Medicine 1998, 4:46-60.
85. Tikellis C., Thomas M.C., Harcourt B.E., Coughlan M.T., Pete J., Bialkowski K., Tan A., Bierhaus A., Cooper M.E., Forbes J.M. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. American Journal of Physiology - Endocrinology and Metabolism 2008, 295:E323-E330.
86. Stitt A.W., He C., Vlassara H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochemical and Biophysical Research Communications 1999, 256:549-556.
87. McFarlane S., Glenn J.V., Lichanska A.M., Simpson D.A., Stitt A.W. Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. British Journal of Ophthalmology 2005, 89:107-112.
88. Bucciarelli L.G., Wendt T., Rong L., Lalla E., Hofmann M.A., Goova M.T., Taguchi A., Yan S.F., Yan S.D., Stern D.M., Schmidt A.M. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cellular and Molecular Life Sciences 2002, 59:1117-1128.
89. Yan S.F., Ramasamy R., Schmidt A.M. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Reviews in Molecular Medicine 2009, 11:e9.
90. Chang P.C., Chen T.H., Chang C.J., Hou C.C., Chan P., Lee H.M. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney International 2004, 65:1664-1675.
91. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. Journal of Biological Chemistry 1997, 272(28):17810-17814.
92. Huttunen H.J., Kuja-Panula J., Rauvala H. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. Journal of Biological Chemistry 2002, 277:38635-38646.
93. Chang J.S., Wendt T., Qu W., Kong L., Zou Y.S., Schmidt A.M., Yan S.F. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circulation Research 2008, 102:905-913.
94. Zeng S., Feirt N., Goldstein M., Guarrera J., Ippagunta N., Ekong U., Dun H., Lu Y., Qu W., Schmidt A.M., Emond J.C. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004, 39:422-432.
95. Indurthi V.S., Leclerc E., Vetter S.W. Interaction between glycated serum albumin and AGE-receptors depends on structural changes and the glycation reagent. Archives of Biochemistry and Biophysics 2012, 528:185-196.
96. Yatime L., Andersen G.R. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS Journal 2013, 280:6556-6568.
97. Sitkiewicz E., Tarnowski K., Poznanski J., Kulma M., Dadlez M. Oligomerization Interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchange. PLoS One 2013, 8:e76353.
98. Xie J., Reverdatto S., Frolov A., Hoffmann R., Burz D.S., Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). Journal of Biological Chemistry 2008, 283:27255-27269.
99. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Journal of Clinical Investigation 2001, 108:949-955.
100. Yan S.F., Ramasamy R., Schmidt A.M. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circulation Research 2010, 106:842-853.
101. Chuah Y.K., Basir R., Talib H., Tie T.H., Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. International Journal of Inflammation 2013, 2013:403460.
102. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., De C.D., De B.G., Muraro R., Bei R., Chiarelli F., Schmidt A.M., Cuccurullo F., Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070-1077.
103. Stern D.M., Yan S.D., Yan S.F., Schmidt A.M. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Research Reviews 2002, 1(1):1-15.
104. Vlassara H., Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning?. Reviews in Endocrine and Metabolic Disorder 2004, 5:181-188.
105. Xue J., Rai V., Singer D., Chabierski S., Xie J., Reverdatto S., Burz D.S., Schmidt A.M., Hoffmann R., Shekhtman A. Advanced glycation end product recognition by the receptor for AGEs. Structure 2011, 19:722-732.
106. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., Hofmann M., Yan S.F., Pischetsrieder M., Stern D., Schmidt A.M. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. Journal of Biological Chemistry 1999, 274(44):31740-31749.
107. Liu H., Yu S., Zhang H., Xu J. Angiogenesis impairment in diabetes: role of methylglyoxal-induced receptor for advanced glycation endproducts, autophagy and vascular endothelial growth factor receptor 2. PLoS One 2012, 7:e46720.
108. Buetler T.M., Leclerc E., Baumeyer A., Latado H., Newell J., Adolfsson O., Parisod V., Richoz J., Maurer S., Foata F., Piguet D., Junod S., Heizmann C.W., Delatour T. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Molecular Nutrition and Food Research 2008, 52:370-378.
109. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
110. Poulsen M.W., Hedegaard R.V., Andersen J.M., de Courten B., Bugel S., Nielsen J., Skibsted L.H., Dragsted L.O. Advanced glycation endproducts in food and their effects on health. Food and Chemical Toxicology 2013, 60:10-37.
111. Buetler T.M., Latado H., Leclerc E., Weigle B., Baumeyer A., Heizmann C.W., Scholz G. Glycolaldehyde-modified beta-lactoglobulin AGEs are unable to stimulate inflammatory signaling pathways in RAGE-expressing human cell lines. Molecular Nutrition and Food Research 2011, 55:291-299.
112. Fa M.L., Schalkwijk C.G., Engelse M., van Hinsbergh V.W. Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thrombosis and Haemostasis 2006, 95:320-328.
113. Valencia J.V., Mone M., Koehne C., Rediske J., Hughes T.E. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Diabetologia 2004, 47:844-852.
114. Penfold S.A., Coughlan M.T., Patel S.K., Srivastava P.M., Sourris K.C., Steer D., Webster D.E., Thomas M.C., MacIsaac R.J., Jerums G., Burrell L.M., Cooper M.E., Forbes J.M. Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney International 2010, 78:287-295.
115. Birlouez-Aragon I., Saavedra G., Tessier F.J., Galinier A., Ait-Ameur L., Lacoste F., Niamba C.N., Alt N., Somoza V., Lecerf J.M. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. American Journal of Clinical Nutrition 2010, 91:1220-1226.
116. Zhou Z., Immel D., Xi C.X., Bierhaus A., Feng X., Mei L., Nawroth P., Stern D.M., Xiong W.C. Regulation of osteoclast function and bone mass by RAGE. Journal of Experimental Medicine 2006, 203:1067-1080.
117. Mamputu J.C., Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. Journal of Leukocyte Biology 2004, 75:1062-1069.
118. Gawlowski T., Stratmann B., Ruetter R., Buenting C.E., Menart B., Weiss J., Vlassara H., Koschinsky T., Tschoepe D. Advanced glycation end products strongly activate platelets. European Journal of Nutrition 2009, 48:475-481.
119. Kirstein M., Brett J., Radoff S., Ogawa S., Stern D., Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:9010-9014.
120. Yu W., Liu-Bryan R., Stevens S., Damanahalli J.K., Terkeltaub R. RAGE signaling mediates post-injury arterial neointima formation by suppression of liver kinase B1 and AMPK activity. Atherosclerosis 2012, 222:417-425.
121. Rojas A., Morales M.A. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sciences 2004, 76:715-730.
122. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. Journal of Clinical Investigation 1995, 96:1395-1403.
123. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., Hori O., Stern D., Schmidt A.M. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. Journal of Clinical Investigation 1996, 97:238-243.
124. Esposito C., Gerlach H., Brett J., Stern D., Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. Journal of Experimental Medicine 1989, 170:1387-1407.
125. Naser N., Januszewski A.S., Brown B.E., Jenkins A.J., Hill M.A., Murphy T.V. Advanced glycation end products acutely impair ca(2+) signaling in bovine aortic endothelial cells. Frontiers in Physiology 2013, 4:38.
126. Duh E., Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999, 48:1899-1906.
127. Peppa M., Brem H., Ehrlich P., Zhang J.G., Cai W., Li Z., Croitoru A., Thung S., Vlassara H. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003, 52:2805-2813.
128. Simons M. Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed?. Journal of the American College of Cardiology 2005, 46:835-837.
129. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nature Reviews Molecular Cell Biology 2006, 7:359-371.
130. Podesta F., Romeo G., Liu W.H., Krajewski S., Reed J.C., Gerhardinger C., Lorenzi M. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. American Journal of Pathology 2000, 156:1025-1032.
131. Nagaraj R.H., Oya-Ito T., Bhat M., Liu B. Dicarbonyl stress and apoptosis of vascular cells: prevention by alphaB-crystallin. Annals of the New York Academy of Sciences 2005, 1043:158-165.
132. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Koga K., Sasaki N., Yamamoto H., Takeuchi M., Makita Z. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochemical and Biophysical Research Communications 2002, 290:973-978.
133. Chibber R., Molinatti P.A., Rosatto N., Lambourne B., Kohner E.M. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997, 40:156-164.
134. Li N., Hu H., Lindqvist M., Wikstrom-Jonsson E., Goodall A.H., Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:2702-2708.
135. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. Journal of Clinical Investigation 2005, 115:3378-3384.
136. Stirban A., Negrean M., Stratmann B., Gawlowski T., Horstmann T., Gotting C., Kleesiek K., Mueller-Roesel M., Koschinsky T., Uribarri J., Vlassara H., Tschoepe D. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006, 29:2064-2071.
137. Negrean M., Stirban A., Stratmann B., Gawlowski T., Horstmann T., Gotting C., Kleesiek K., Mueller-Roesel M., Koschinsky T., Uribarri J., Vlassara H., Tschoepe D. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. American Journal of Clinical Nutrition 2007, 85:1236-1243.
138. Zhu W., Li W., Silverstein R.L. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012, 119:6136-6144.
139. Schmidt A.M., Yan S.D., Brett J., Mora R., Nowygrod R., Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. Journal of Clinical Investigation 1993, 91:2155-2168.
140. Vlassara H., Brownlee M., Manogue K.R., Dinarello C.A., Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988, 240:1546-1548.
141. Kirstein M., Aston C., Hintz R., Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. Journal of Clinical Investigation 1992, 90:439-446.
142. Khechai F., Ollivier V., Bridey F., Amar M., Hakim J., de P.D. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation. Arteriosclerosis, Thrombosis, and Vascular Biology 1997, 17:2885-2890.
143. Gawlowski T., Stratmann B., Stirban A.O., Negrean M., Tschoepe D. AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet-neutrophil aggregation. Thrombosis Research 2007, 121:117-126.
144. Bierhaus A., Illmer T., Kasper M., Luther T., Quehenberger P., Tritschler H., Wahl P., Ziegler R., Muller M., Nawroth P.P. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997, 96:2262-2271.
145. Misumi K., Ogawa H., Yasue H., Soejima H., Suefuji H., Nishiyama K., Takazoe K., Kugiyama K., Tsuji I., Kumeda K., Nakamura S. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. American Journal of Cardiology 1998, 81:22-26.
146. Seljeflot I., Hurlen M., Hole T., Arnesen H. Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thrombosis Research 2003, 111:369-372.
147. Hu H., Li N., Yngen M., Ostenson C.G., Wallen N.H., Hjemdahl P. Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus: relationship to microangiopathy. Journal of Thrombosis and Haemostasis 2004, 2:58-64.
148. Zhang L., Zalewski A., Liu Y., Mazurek T., Cowan S., Martin J.L., Hofmann S.M., Vlassara H., Shi Y. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 2003, 108:472-478.
149. Wang Z., Jiang Y., Liu N., Ren L., Zhu Y., An Y., Chen D. Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012, 221:387-396.
150. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Laboratory Investigation 1994, 70:138-151.
151. Li Y., Liu S., Zhang Z., Xu Q., Xie F., Wang J., Ping S., Li C., Wang Z., Zhang M., Huang J., Chen D., Hu L., Li C. RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation. PLoS One 2012, 7:e35016.
152. Hu P., Lai D., Lu P., Gao J., He H. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. International Journal of Molecular Medicine 2012, 29:613-618.
153. Yuan X., Zhang Z., Gong K., Zhao P., Qin J., Liu N. Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats. Biological and Pharmaceutical Bulletin 2011, 34:618-623.
154. Meloche J., Paulin R., Courboulin A., Lambert C., Barrier M., Bonnet P., Bisserier M., Roy M., Sussman M.A., Agharazii M., Bonnet S. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:2114-2124.
155. Chang T., Wang R., Olson D.J., Mousseau D.D., Ross A.R., Wu L. Modification of Akt1 by methylglyoxal promotes the proliferation of vascular smooth muscle cells. FASEB Journal 2011, 25:1746-1757.
156. Suga T., Iso T., Shimizu T., Tanaka T., Yamagishi S., Takeuchi M., Imaizumi T., Kurabayashi M. Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. Journal of Atherosclerosis and Thrombosis 2011, 18:670-683.
157. Benzaquen L.R., Nicholson-Weller A., Halperin J.A. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. Journal of Experimental Medicine 1994, 179:985-992.
158. Acosta J., Hettinga J., Fluckiger R., Krumrei N., Goldfine A., Angarita L., Halperin J. Molecular basis for a link between complement and the vascular complications of diabetes. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:5450-5455.
159. Stitt A.W., He C., Friedman S., Scher L., Rossi P., Ong L., Founds H., Li Y.M., Bucala R., Vlassara H. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Molecular Medicine 1997, 3:617-627.
160. Niwa T., Katsuzaki T., Miyazaki S., Miyazaki T., Ishizaki Y., Hayase F., Tatemichi N., Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. Journal of Clinical Investigation 1997, 99:1272-1280.
161. Nakamura Y., Horii Y., Nishino T., Shiiki H., Sakaguchi Y., Kagoshima T., Dohi K., Makita Z., Vlassara H., Bucala R. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. American Journal of Pathology 1993, 143:1649-1656.
162. Lin R.Y., Choudhury R.P., Cai W., Lu M., Fallon J.T., Fisher E.A., Vlassara H. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003, 168:213-220.
163. Hofmann S.M., Dong H.J., Li Z., Cai W., Altomonte J., Thung S.N., Zeng F., Fisher E.A., Vlassara H. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002, 51:2082-2089.
164. Lin R.Y., Reis E.D., Dore A.T., Lu M., Ghodsi N., Fallon J.T., Fisher E.A., Vlassara H. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002, 163:303-311.
165. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:12043-12047.
166. Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
167. Li Y.M., Steffes M., Donnelly T., Liu C., Fuh H., Basgen J., Bucala R., Vlassara H. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3902-3907.
168. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J., Chow W.S., Stern D., Schmidt A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 1998, 4:1025-1031.
169. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran L.J., Taguchi A., Olson K., Bucciarelli L., Goova M., Hofmann M.A., Cataldegirmen G., D'Agati V., Pischetsrieder M., Stern D.M., Schmidt A.M. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21:905-910.
170. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., Goova M.T., Moser B., Kislinger T., Lee D.C., Kashyap Y., Stern D.M., Schmidt A.M. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
171. Wendt T., Harja E., Bucciarelli L., Qu W., Lu Y., Rong L.L., Jenkins D.G., Stein G., Schmidt A.M., Yan S.F. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006, 185:70-77.
172. Kiuchi K., Nejima J., Takano T., Ohta M., Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 2001, 85:87-91.
173. Kilhovd B.K., Berg T.J., Birkeland K.I., Thorsby P., Hanssen K.F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999, 22:1543-1548.
174. Aso Y., Inukai T., Tayama K., Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetologica 2000, 37:87-92.
175. Choi E.Y., Kwon H.M., Ahn C.W., Lee G.T., Joung B., Hong B.K., Yoon Y.W., Kim D., Byun K.H., Kang T.S., Yoon S.J., Kwon S.W., Lee S.J., Park J.K., Kim H.S. Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients. Yonsei Medical Journal 2005, 46:78-85.
176. Kilhovd B.K., Juutilainen A., Lehto S., Ronnemaa T., Torjesen P.A., Hanssen K.F., Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007, 50:1409-1417.
177. Kilhovd B.K., Juutilainen A., Lehto S., Ronnemaa T., Torjesen P.A., Birkeland K.I., Berg T.J., Hanssen K.F., Laakso M. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:815-820.
178. Hartog J.W., Voors A.A., Schalkwijk C.G., Scheijen J., Smilde T.D., Damman K., Bakker S.J., Smit A.J., Van Veldhuisen D.J. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. European Heart Journal 2007, 28:2879-2885.
179. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield J.E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. Journal of the American College of Cardiology 1994, 24:1468-1474.
180. Hadi H.A., Carr C.S., Al S.J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Journal of Vascular Health and Risk Management 2005, 1:183-198.
181. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. Journal of Molecular and Cellular Cardiology 1999, 31:23-37.
182. Stirban, A., Kotsi, P., Franke, K., Strijowski, U., Cai, W., Götting, C., Tschoepe, D., 2013. Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins. Diabetes Care 36:1278-1282.
183. Noordzij M.J., Lefrandt J.D., Loeffen E.A., Saleem B.R., Meerwaldt R., Lutgers H.L., Smit A.J., Zeebregts C.J. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. International Journal of Cardiovascular Imaging 2012, 28:431-438.
184. Mulder D.J., van Haelst P.L., Graaff R., Gans R.O., Zijlstra F., Smit A.J. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Netherlands Heart Journal 2009, 17:162-168.
185. Lutgers H.L., Gerrits E.G., Graaff R., Links T.P., Sluiter W.J., Gans R.O., Bilo H.J., Smit A.J. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009, 52:789-797.
186. Uribarri J., Cai W., Ramdas M., Goodman S., Pyzik R., Chen X., Zhu L., Striker G.E., Vlassara H. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011, 34:1610-1616.
187. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine 2003, 9:294-299.
188. Stracke H., Hammes H.P., Werkmann D., Mavrakis K., Bitsch I., Netzel M., Geyer J., Kopcke W., Sauerland C., Bretzel R.G., Federlin K.F. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Experimental and Clinical Endocrinology and Diabetes 2001, 109:330-336.
189. Karachalias N., Babaei-Jadidi R., Kupich C., Ahmed N., Thornalley P.J. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Annals of the New York Academy of Sciences 2005, 1043:777-783.
190. Rahbar S., Figarola J.L. Novel inhibitors of advanced glycation endproducts. Archives of Biochemistry and Biophysics 2003, 419:63-79.
191. Monnier V.M. Intervention against the Maillard reaction in vivo. Archives of Biochemistry and Biophysics 2003, 419:1-15.
192. Bierhaus A., Fleming T., Stoyanov S., Leffler A., Babes A., Neacsu C., Sauer S.K., Eberhardt M., Schnolzer M., Lasitschka F., Neuhuber W.L., Kichko T.I., Konrade I., Elvert R., Mier W., Pirags V., Lukic I.K., Morcos M., Dehmer T., Rabbani N., Thornalley P.J., Edelstein D., Nau C., Forbes J., Humpert P.M., Schwaninger M., Ziegler D., Stern D.M., Cooper M.E., Haberkorn U., Brownlee M., Reeh P.W., Nawroth P.P. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine 2012, 18:926-933.
193. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993, 329:977-986.
194. Pop-Busui R., Herman W.H., Feldman E.L., Low P.A., Martin C.L., Cleary P.A., Waberski B.H., Lachin J.M., Albers J.W. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Current Diabetes Reports 2010, 10:276-282.
195. Jax T.W. Metabolic memory: a vascular perspective. Cardiovascular Diabetology 2010, 9:51.